OBJECTIVE: To estimate prevalence of hepatitis C virus (HCV) infection and identify risk factors associated and circulating HCV genotypes and subtypes. METHODS: Study conducted including 691 drug users attending 26 charitable, private and public drug treatment centers in Goiânia and Campo Grande, central-western Brazil, between 2005 and 2006. Sociodemographic characteristics and risk factors for HCV infection were collected during interviews. Blood samples were tested for HCV antibodies (anti-HCV). Positive samples were submitted to HCV RNA detection by PCR with primers complementary to 5' NC and NS5B regions of viral genome and genotyped by line probe assay (LiPA) and direct nucleotide sequencing followed by phylogenetic analysis. The prevalence and odds ratio were calculated with 95% confidence intervals. Risk factors were first estimated in the univariate analysis (p<0.10) and then analyzed by hierarchical logistic regression. Statistical significance was assessed at a 5% significance level. RESULTS: The prevalence of anti-HCV was 6.9% (95% CI: 5.2-9.2). The multivariate analysis of risk factors revealed that age over 30 years and injecting drug use were associated with HCV infection. HCV RNA was detected in 85.4% (41/48) of anti-HCV-positive samples. Thirty-three samples were genotyped as genotype 1 by LiPA, subtypes 1a (63.4%) and 1b (17.1%), and 8 samples (19.5%) were genotype 3, subtype 3a. The phylogenetic analysis of the NS5B region showed that 17 (68%), 5 (20%), and 3 (12%) samples were subtypes 1a, 3a, and 1b, respectively. CONCLUSIONS: The results show a high prevalence of HCV infection and predominance of subtype 1a among drug users in Brazil. In addition, injecting drug use was a major risk factor associated with HCV infection.
OBJECTIVE: To estimate prevalence of hepatitis C virus (HCV) infection and identify risk factors associated and circulating HCV genotypes and subtypes. METHODS: Study conducted including 691 drug users attending 26 charitable, private and public drug treatment centers in Goiânia and Campo Grande, central-western Brazil, between 2005 and 2006. Sociodemographic characteristics and risk factors for HCV infection were collected during interviews. Blood samples were tested for HCV antibodies (anti-HCV). Positive samples were submitted to HCV RNA detection by PCR with primers complementary to 5' NC and NS5B regions of viral genome and genotyped by line probe assay (LiPA) and direct nucleotide sequencing followed by phylogenetic analysis. The prevalence and odds ratio were calculated with 95% confidence intervals. Risk factors were first estimated in the univariate analysis (p<0.10) and then analyzed by hierarchical logistic regression. Statistical significance was assessed at a 5% significance level. RESULTS: The prevalence of anti-HCV was 6.9% (95% CI: 5.2-9.2). The multivariate analysis of risk factors revealed that age over 30 years and injecting drug use were associated with HCV infection. HCV RNA was detected in 85.4% (41/48) of anti-HCV-positive samples. Thirty-three samples were genotyped as genotype 1 by LiPA, subtypes 1a (63.4%) and 1b (17.1%), and 8 samples (19.5%) were genotype 3, subtype 3a. The phylogenetic analysis of the NS5B region showed that 17 (68%), 5 (20%), and 3 (12%) samples were subtypes 1a, 3a, and 1b, respectively. CONCLUSIONS: The results show a high prevalence of HCV infection and predominance of subtype 1a among drug users in Brazil. In addition, injecting drug use was a major risk factor associated with HCV infection.
Authors: Bruno Fernandes de Oliveira Santos; Nathalie Oliveira de Santana; Alex Vianey Callado Franca Journal: World J Gastroenterol Date: 2011-07-07 Impact factor: 5.742
Authors: Camila Malta Romano; Isabel M V Guedes de Carvalho-Mello; Leda F Jamal; Fernando Lucas de Melo; Atila Iamarino; Marco Motoki; João Renato Rebello Pinho; Edward C Holmes; Paolo Marinho de Andrade Zanotto Journal: PLoS One Date: 2010-06-23 Impact factor: 3.240
Authors: David Toro-Tobón; Dedsy Berbesi-Fernandez; Pedro Mateu-Gelabert; Ángela M Segura-Cardona; Liliana P Montoya-Vélez Journal: Int J Drug Policy Date: 2018-08-11
Authors: Nara R Freitas; Sheila A Teles; Marcos A Matos; Carmen Lr Lopes; Nádia Rs Reis; Márcia P Espírito-Santo; Elisabeth Lampe; Regina Mb Martins Journal: Virol J Date: 2010-08-27 Impact factor: 4.099
Authors: Monica Alonso; Annika Gutzman; Rafael Mazin; Carlos E Pinzon; Ludovic Reveiz; Massimo Ghidinelli Journal: Int J Public Health Date: 2015-08-23 Impact factor: 3.380
Authors: Aldemir B Oliveira-Filho; Leila Sawada; Laine C Pinto; Daiane Locks; Santana L Bahia; Jairo A A Castro; Renata B Hermes; Igor Brasil-Costa; Carlos E M Amaral; José Alexandre R Lemos Journal: Virol J Date: 2014-02-25 Impact factor: 4.099
Authors: Leila M M B Pereira; Celina M T Martelli; Regina C Moreira; Edgar Merchan-Hamman; Airton T Stein; Maria Regina A Cardoso; Gerusa M Figueiredo; Ulisses R Montarroyos; Cynthia Braga; Marília D Turchi; Gabriela Coral; Deborah Crespo; Maria Luiza C Lima; Luis Claudio A Alencar; Marcelo Costa; Alex A dos Santos; Ricardo A A Ximenes Journal: BMC Infect Dis Date: 2013-02-01 Impact factor: 3.090
Authors: Anna S Nishiya; Cesar de Almeida-Neto; Suzete C Ferreira; Cecília S Alencar; Claudia Di-Lorenzo-Oliveira; José E Levi; Nanci A Salles; Alfredo Mendrone; Ester C Sabino Journal: PLoS One Date: 2014-01-21 Impact factor: 3.240